Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2214 versus placebo in early Alzheimer's disease
NL-OMON60686Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing MK-2214 with Placebo (2 arms). Primary endpoints: Change from baseline in tau positron emission tomography standardized uptake value ratio, Number of participants with one or more adverse events and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
mk-2214
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON60686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60686.